BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case
M. M. Davydov,
P. A. Zeynalova,
A. A. Fedenko,
D. A. Chekiny,
E. K. Ibragimov,
A. A. Filimonov,
O. V. Sinitsyna,
E. A. Bogush,
M. A. Chekalova,
G. F. Allakhverdieva,
M. V. Shamanova,
I. V. Zhguleva,
V. Yu. Kirsanov,
V. E. Ponomarev,
S. B. Polikarpova,
T. T. Valiev,
M. A. Kurtser https://doi.org/10.17650/2782-3202-2021-1-1-38-42
Abstract
Per the majority of authors, melanoma is the most common tumor diagnosed during pregnancy (31 % of all malignant neoplasms). In approximately 1/3 of women melanoma developed in child-bearing age is diagnosed during pregnancy or in the postpartum period. However, only some retrospective studies analyzed the effect of pregnancy on melanoma development, and conclusive data on development, progression and treatment of BRAF-mutant melanoma is lacking. In this subpopulation of patients, BRAF status supposedly can negatively affect disease outcome irrespective of treatment methods.
The article presents a clinical case of recurrence of melanoma with the BRAF V600E mutation during pregnancy. The patient underwent lymph node dissection during pregnancy prolongation, after labor she received antitumor drug therapy with МЕК and ВRAF inhibitors. Melanoma recurrence during pregnancy did not worsen treatment outcomes for the mother and embryo.
About the Authors
M. M. Davydov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia
A. A. Fedenko
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
D. A. Chekiny
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
E. K. Ibragimov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
A. A. Filimonov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
O. V. Sinitsyna
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
E. A. Bogush
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia
M. A. Chekalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
G. F. Allakhverdieva
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
M. V. Shamanova
Clinical Hospital MD GROUP
Russian Federation
Russian Federation
Bld. 1, 24 Sevastopolsky Ave, Moscow 117209, Russia
I. V. Zhguleva
Clinical Hospital MD GROUP
Russian Federation
Russian Federation
Bld. 1, 24 Sevastopolsky Ave, Moscow 117209, Russia
V. Yu. Kirsanov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia
V. E. Ponomarev
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia
S. B. Polikarpova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia
T. T. Valiev
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia
M. A. Kurtser
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia
1 Ostrovityanova St., Moscow 117997, Russia
References
1. De Haan J., van Thienen J.V., Casaer M. et al. Severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma. Case Rep Oncol 2018;11(1):119–24. DOI: 10.1159/000487128.
2. Bucheit A.D., Hardy J.T., Szender J.B. et al. Conception and viable twin pregnancy in a patient with metastatic melanoma treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res 2020;30(4):423–5. DOI: 10.1097/CMR.0000000000000657.
3. Ziogas D.C., Diamantopoulos P., Benopoulou O. et al. Prognosis and management of BRAF V600E-mutated pregnancy-associated melanoma. Oncol 2020;25(8):1209–20. DOI: 10.1634/theoncologist.2019-0747.
4. Jones M.S., Lee J., Stern S.L. et al. Is pregnancy-associated melanoma associated with adverse outcomes? J Am Coll Surg 2017;225(1):149–58. DOI: 10.1016/j.jamcollsurg.2017.02.011.
5. Todd S.P., Driscoll M.S. Prognosis for women diagnosed with melanoma during, before, or after pregnancy: weighing the evidence. Int J Womens Dermatol 2017;3(1):26–9. DOI: 10.1016/j.ijwd.2016.12.004.
6. Zelin E., Conforti C., Giuffrida R. et al. Melanoma in pregnancy: certainties unborn. Melanoma Manag 2020;7(3):MMT48. DOI: 10.2217/mmt-2020-0007.
7. Kyrgidis A., Lallas A., Moscarella E. Does pregnancy influence melanoma prognosis? A meta-analysis. Melanoma Res 2017;27(4):289–99. DOI: 10.1097/CMR.0000000000000334.
8. Walker J.L., Wang A.R., Kroumpouzos G., Weinstok M.A. Melanoma in pregnancy. In: Melanoma: a modern multidisciplinary approach. Ed by A.I. Riker. Springer, Cham, 2018. Pp. 239–252.
9. Still R., Brennecke S. Melanoma in pregnancy. Obstet Med 2017;10(3):107–12. DOI: 10.1177/1753495X17695001.
10. Garbe C., Amaral T., Peris K. et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. Eur J Cancer 2020;126:141–58. DOI: 10.1016/j.ejca.2019.11.014.
11. Ribero S., Longo C., Dika Е. et al. Pregnancy and melanoma: a European-wide survey to assess current management and critical literature overview. J Eur Acad Dermatol Venereol 2017;31(1):65–9. DOI: 10.1111/jdv.13722.
12. Menzer C., Beedgen B., Rom J. et al. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. Eur J Cancer 2018;104:239–42. DOI: 10.1016/j.ejca.2018.09.008.
13. Xu W., Moor R.J., Walpole E.T. et al. Pregnancy with successful fetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: Case report and review of the literature. Melanoma Res 2019;29(3):333–7. DOI: 10.1097/CMR.0000000000000586.
14. Mehta A., Kim K.B., Minor D.R. Case report of a pregnancy during ipilimumab therapy. J Glob Oncol 2018;4:1–3. DOI: 10.1200/JGO.17.00019.
15. Burotto M., Gormas J.G., Samtani S. et al. Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Semin Oncol 2018;45(3):164–9. DOI: 10.1053/j.seminoncol.2018.03.003.
16. Sacchetto L., Zanetti R., Comber H. et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018;92:108–18. DOI: 10.1016/j.ejca.2017.12.024
Review
For citations:
Davydov M.M., Zeynalova P.A., Fedenko A.A., Chekiny D.A., Ibragimov E.K., Filimonov A.A., Sinitsyna O.V., Bogush E.A., Chekalova M.A., Allakhverdieva G.F., Shamanova M.V., Zhguleva I.V., Kirsanov V.Yu., Ponomarev V.E., Polikarpova S.B., Valiev T.T., Kurtser M.A. BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case. MD-Onco. 2021;1(1):38-42. (In Russ.) https://doi.org/10.17650/2782-3202-2021-1-1-38-42
Views:
328
Email this article 